{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:32:34Z","timestamp":1793727154435,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1038\/s41591-023-02228-4","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T12:03:13Z","timestamp":1677758593000},"page":"574-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Predicting the efficacy of variant-modified COVID-19 vaccine boosters"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-1551","authenticated-orcid":false,"given":"David S.","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-5504","authenticated-orcid":false,"given":"Steffen S.","family":"Docken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-3056","authenticated-orcid":false,"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-4891","authenticated-orcid":false,"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1831","authenticated-orcid":false,"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-5094","authenticated-orcid":false,"given":"Deborah","family":"Cromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"2228_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJMc2206711","volume":"387","author":"O Launay","year":"2022","unstructured":"Launay, O. et al. Immunogenicity and safety of Beta-adjuvanted recombinant booster vaccine. N. Engl. J. Med. 387, 374\u2013376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2228_CR2","unstructured":"Branche, A. R. et al. SARS-CoV-2 variant vaccine boosters trial: preliminary analyses. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2022.07.12.22277336v1 (2022)."},{"key":"2228_CR3","doi-asserted-by":"crossref","unstructured":"Chalkias, S. et al. Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine. Nat. Med. 28, 2388\u20132397 (2022).","DOI":"10.1038\/s41591-022-02031-7"},{"key":"2228_CR4","doi-asserted-by":"crossref","unstructured":"Chalkias, S. et al. A bivalent Omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","DOI":"10.1056\/NEJMoa2208343"},{"key":"2228_CR5","unstructured":"Moderna. Moderna\u2019s omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrates significantly higher neutralizing antibody response against Omicron subvariants BA.4\/5 compared To currently authorized booster. Moderna https:\/\/www.accesswire.com\/708109\/Modernas-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273214-Demonstrates-Significantly-Higher-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA45-Compared-To-Currently-Authorized-Booster (2022)."},{"key":"2228_CR6","unstructured":"Swanson, K. A. Meeting Presentation Pfizer\/BioNTech COVID-19 Omicron-Modified Vaccine Options (Vaccines and Related Biological Products Advisory Committee, 2022)."},{"key":"2228_CR7","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","volume":"27","author":"A Choi","year":"2021","unstructured":"Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat. Med. 27, 2025\u20132031 (2021).","journal-title":"Nat. Med."},{"key":"2228_CR8","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMc2119912","volume":"386","author":"R Pajon","year":"2022","unstructured":"Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088\u20131091 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2228_CR9","doi-asserted-by":"crossref","unstructured":"Wang, Q. et al. Antibody responses to Omicron BA.4\/BA.5 bivalent mRNA vaccine booster shot. N. Engl. J. Med. 388, 567\u2013569 (2023).","DOI":"10.1056\/NEJMc2213907"},{"key":"2228_CR10","doi-asserted-by":"crossref","unstructured":"Collier, A. Y. et al. Immunogenicity of the BA.5 bivalent mRNA vaccine boosters. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2022.10.24.513619v1 (2022).","DOI":"10.1101\/2022.10.24.513619"},{"key":"2228_CR11","doi-asserted-by":"crossref","unstructured":"Miller, J. et al. Substantial neutralization escape by the SARS-CoV-2 Omicron variant BQ.1.1. N. Engl. J. Med. 388, 662\u2013664 (2023).","DOI":"10.1056\/NEJMc2214314"},{"key":"2228_CR12","doi-asserted-by":"publisher","unstructured":"Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-02162-x (2022).","DOI":"10.1038\/s41591-022-02162-x"},{"key":"2228_CR13","doi-asserted-by":"crossref","unstructured":"Davis-Gardner, M. E. et al. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2022.10.31.514636v1 (2022).","DOI":"10.1101\/2022.10.31.514636"},{"key":"2228_CR14","unstructured":"Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4\/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine. GlobeNewswire https:\/\/www.globenewswire.com\/en\/news-release\/2022\/11\/04\/2548600\/0\/en\/Pfizer-and-BioNTech-Announce-Updated-Clinical-Data-for-Omicron-BA-4-BA-5-Adapted-Bivalent-Booster-Demonstrating-Substantially-Higher-Immune-Response-in-Adults-Compared-to-the-Origi.html (2022)."},{"key":"2228_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"2228_CR16","doi-asserted-by":"crossref","unstructured":"Cromer, D. et al. Neutralising antibodies predict protection from severe COVID-19. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2022.06.09.22275942v1 (2022).","DOI":"10.1101\/2022.06.09.22275942"},{"key":"2228_CR17","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"2228_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3201\/eid2902.221422","volume":"29","author":"DS Khoury","year":"2022","unstructured":"Khoury, D. S. et al. Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV- 2 infection. Emerg. Infect. Dis. 29, 381\u2013388 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"2228_CR19","doi-asserted-by":"crossref","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).","DOI":"10.1126\/science.abf4063"},{"key":"2228_CR20","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1093\/cid\/ciac075","volume":"75","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial. Clin. Infect. Dis. 75, e878\u2013e879 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"2228_CR21","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"2228_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s43588-022-00198-0","volume":"2","author":"P Padmanabhan","year":"2022","unstructured":"Padmanabhan, P., Desikan, R. & Dixit, N. M. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. Nat. Comput. Sci. 2, 123\u2013131 (2022).","journal-title":"Nat. Comput. Sci."},{"key":"2228_CR23","doi-asserted-by":"crossref","unstructured":"Kandala, B. et al. Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. EBioMedicine 84, 104264 (2022).","DOI":"10.1016\/j.ebiom.2022.104264"},{"key":"2228_CR24","doi-asserted-by":"crossref","unstructured":"Khoury, D. S. et al. A meta-analysis of early results to predict vaccine efficacy against Omicron. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2021.12.13.21267748v1 (2021).","DOI":"10.1101\/2021.12.13.21267748"},{"key":"2228_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"2228_CR26","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"2228_CR27","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","volume":"7","author":"Y Fong","year":"2022","unstructured":"Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 7, 1996\u20132010 (2022).","journal-title":"Nat. Microbiol."},{"key":"2228_CR28","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).","journal-title":"Science"},{"key":"2228_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).","journal-title":"Nat. Commun."},{"key":"2228_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41577-022-00716-1","volume":"22","author":"SJ Kent","year":"2022","unstructured":"Kent, S. J. et al. Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? Nat. Rev. Immunol. 22, 387\u2013397 (2022).","journal-title":"Nat. Rev. Immunol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02228-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T10:17:11Z","timestamp":1679480231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02228-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2228"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02228-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.08.25.22279237","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}